The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i
The model's full reasoning — Q2 2022 call → NOWe need to determine if there is a specific negative outcome that investors/analysts/market are worried about, and management pushes back with current observed evidence. The transcript shows strong results, acceleration, etc. Analysts ask about growth sustainability, net adds, competition, etc. But is there a specific fear? For example, Brent Bracelin asks about enterprise expansions, why now. Not a fear. Steve Enders asks about net retention drivers. Not a fear. Brent Thill asks about billings and guidance, noting deceleration in Q4. That could be a worry about growth deceleration. Tim responds by saying they are encouraged, increased guidance, etc. But does he cite observed evidence? He mentions RPO growth, but not specific observed behavior. Also, the question about whether growth is a one-time bulge? Keith Weiss asks about pent-up demand and whether trends are durable. Dustin says it's not pent-up demand, it's category maturing, and points to record top of funnel, etc. But is that observed evidence? He says "record top of funnel" and "big deals in future" but not specific current evidence. Also, the fear of deceleration in Q4 is mentioned by analyst, but management doesn't directly counter with observed evidence; they just say they raised guidance. Another possible fear: competition? Not really. The call is all positive. The only negative is the Q4 deceleration implied by guidance, but management doesn't address it with evidence. Also, the question about billings: Brent Thill notes 18% billings vs 59% guide. That could be a worry about growth sustainability. Tim says billings not best indicator because monthly SKUs, and points to RPO growth. But is that observed evidence? RPO is a current metric, but it's not a specific behavior like renewals or expansions. It's a financial metric. The instruction says "observed behavior" like customers renewing, reordering, expanding. RPO is a contract metric, but it's not specific to a fear being countered. The fear must be "live on the call" and management must push back with "already-observed evidence". I don't see a clear specific fear that analysts keep probing. They ask about drivers, but not fears. The only hint is the deceleration in Q4, but management doesn't directly address it with evidence. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AVTR | Avantor, Inc. | Q2 2024 | 2024-07-26 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| TYGO | Tigo Energy, Inc. | Q4 2023 | 2024-02-14 | F |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| BBVA | Banco Bilbao Vizcaya Argentaria, S.A. | Q4 2023 | 2024-01-30 | B+ |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| GMED | Globus Medical, Inc. | Q3 2023 | 2023-11-07 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| MAC | The Macerich Company | Q3 2023 | 2023-10-31 | D |
| LNTH | Lantheus Holdings, Inc. | Q2 2023 | 2023-08-03 | C+ |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| TREX | Trex Company, Inc. | Q2 2023 | 2023-07-31 | B+ |
| REYN | Reynolds Consumer Products Inc. | Q1 2023 | 2023-05-10 | C |
| DOCN | DigitalOcean Holdings, Inc. | Q1 2023 | 2023-05-09 | C+ |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| AKR | Acadia Realty Trust | Q4 2022 | 2023-05-06 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| EPR | EPR Properties | Q1 2023 | 2023-04-27 | C+ |
| MEDP | Medpace Holdings, Inc. | Q1 2023 | 2023-04-25 | B+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| POOL | Pool Corporation | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| REGN | Regeneron Pharmaceuticals, Inc. | Q4 2022 | 2023-02-03 | C |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| A | Agilent Technologies, Inc. | Q4 2022 | 2022-11-21 | B+ |
| PCTY | Paylocity Holding Corporation | Q1 2023 | 2022-11-05 | A |
| TT | Trane Technologies plc | Q3 2022 | 2022-11-02 | A |
| APOG | Apogee Enterprises, Inc. | Q2 2023 | 2022-09-20 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| ZBRA | Zebra Technologies Corporation | Q2 2022 | 2022-08-02 | C+ |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| SHW | The Sherwin-Williams Company | Q2 2022 | 2022-07-27 | D |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| DCGO | DocGo Inc. | Q1 2022 | 2022-05-14 | C |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| EGHT | 8x8, Inc. | Q4 2022 | 2022-05-10 | C+ |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| BSX | Boston Scientific Corporation | Q1 2022 | 2022-04-27 | B |
| CCK | Crown Holdings, Inc. | Q1 2022 | 2022-04-26 | C+ |
| FR | First Industrial Realty Trust, Inc. | Q1 2022 | 2022-04-21 | A |
| SDIG | Stronghold Digital Mining, Inc. | Q3 2021 | 2021-11-30 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| HSY | The Hershey Company | Q3 2021 | 2021-10-28 | C |
| PEP | PepsiCo, Inc. | Q3 2021 | 2021-10-05 | B |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| PTVE | Pactiv Evergreen Inc. | Q2 2021 | 2021-08-08 | C+ |
| SPG | Simon Property Group, Inc. | Q2 2021 | 2021-08-02 | B |
| GLW | Corning Incorporated | Q2 2021 | 2021-07-27 | B+ |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| VLRS | Controladora Vuela Compañía de Aviación, | Q2 2021 | 2021-07-16 | B+ |
| MAR | Marriott International, Inc. | Q2 2018 | 2018-08-07 | B |
| VALE | Vale S.A. | Q2 2018 | 2018-07-26 | B |
| FICO | Fair Isaac Corporation | Q3 2018 | 2018-07-26 | C+ |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| TRUE | TrueCar, Inc. | Q1 2018 | 2018-05-08 | C |
| TGNA | TEGNA Inc. | Q1 2018 | 2018-05-08 | B+ |
| CVS | CVS Health Corporation | Q1 2018 | 2018-05-02 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| MIDD | The Middleby Corporation | Q4 2017 | 2018-02-28 | C |
| SBUX | Starbucks Corporation | Q1 2018 | 2018-01-26 | C |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| GURE | Gulf Resources, Inc. | Q3 2017 | 2017-11-14 | F |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCRX | BioCryst Pharmaceuticals, Inc. | Q1 2017 | 2017-05-07 | B |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| CGNT | Cognyte Software Ltd. | Q4 2016 | 2017-03-09 | D |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| SEM | Select Medical Holdings Corporation | Q1 2016 | 2016-05-06 | C+ |
| LPSN | LivePerson, Inc. | Q1 2016 | 2016-05-04 | B |
| UVE | Universal Insurance Holdings, Inc. | Q1 2016 | 2016-05-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| VRTS | Virtus Investment Partners, Inc. | Q1 2016 | 2016-04-29 | D |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| BX | Blackstone Inc. | Q1 2016 | 2016-04-21 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.